Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H3B-8800 in MDS, AML, and CMML
NCT02841540Phase 1Terminated
- Sponsor
- Hemavant Sciences
- Start
- Oct 2016
- Primary completion
- Feb 2024
- Modality
- RNA-Targeting Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of H3B-8800 in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML) (3 arms), sponsored by Hemavant Sciences. Primary endpoints: Dose-limiting Toxicities at 28 days and Treatment Emergent Adverse Events and Serious Adverse Events at 50 months. Started Oct 2016; status: terminated.
02
Drugs
H3B-8800
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT02841540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02841540.